# Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer

> **NCT04225026** · PHASE2 · TERMINATED · sponsor: **Galera Therapeutics, Inc.** · enrollment: 39 (actual)

## Conditions studied

- Esophagitis

## Interventions

- **DRUG:** GC4419 (avasopasem manganese)

## Key facts

- **NCT ID:** NCT04225026
- **Lead sponsor:** Galera Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-19
- **Primary completion:** 2021-12-28
- **Final completion:** 2022-03-27
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Lack of study enrollment
- **Last updated:** 2023-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04225026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04225026, "Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04225026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*